Real-world graft utilization after CTN-1101: a registry-based analysis of haploidentical graft versus umbilical cord blood trends

• by Danh T. Tran, Ruyun Jin, Hong Zhu, Gabrielle Schmidt, Stephen R. Spellman, Karen K. Ballen

• August 18, 2025

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

• by Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage

• January 28, 2026

Bone Marrow Transplant: How Keck Medicine of USC Is Excelling in Survival Outcomes

Preet M. Chaudhary, MD, PhD, discusses the repeat ranking of the USC Norris Blood and Marrow Transplant and Cell Therapy Program as one of the nation’s elite allogeneic transplant programs with the highest survival outcomes.

• by

• February 13, 2026

• 12 min

Mechanisms of kinase inhibitor resistance in subtypes of cutaneous T-cell lymphomas

• by Julia A. Yescas, Christopher G. Bunick, Ayman Grada, Joan Guitart, Carlos A. Torres-Cabala, I. Caroline Le Poole, Xiaolong A. Zhou

• May 13, 2026